1. Medtech Insight
  2. >>Archive

Extremity Implants Poised For Strong Growth As Ortho Market Evolves

In the joint reconstruction industry, the extremities market stands out as one area that is expected to continue to perform well, with newer and better technologies driving increased procedural growth and market penetration.

As the adult orthopedic reconstruction market emerges from the doldrums and begins to gain steam, the extremities segment continues to stand out as an area of growth and opportunity. Growth in the overall extremities market remains in the high single-digits, at about 8% worldwide in 2012, driven in part by higher-priced reverse shoulders and total ankles. (See Also see "Orthopedic Implants: Interest Expands In Reverse Shoulders" - Medtech Insight, 28 March, 2012. and Also see "Smaller Players Find Opportunity In Large Joints" - Medtech Insight, 25 May, 2012..)

According to BioMedGPS’ SmartTRAK Extremities module, US shoulder replacement revenues will grow nearly 10% to reach over $620 million during 2012, while the ankle replacement segment is expected to reach nearly $50 million with 12% to13% growth

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By Shubham Singh

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

Does Makary’s Reorg Choice Mark FDA Turning Point?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.